These 3 Healthcare Stocks We’re Avoiding Due to Underwhelming Growth Potential
Healthcare Stocks Pushing the Envelope
The healthcare industry has seen its fair share of innovations in recent years, from the development of new drugs to advancements in digital health. However, not all companies have been able to keep pace with the momentum. In fact, over the past six months, several major players in this space have experienced significant downturns.
One area where the industry has struggled is in areas heavily impacted by COVID-19-related issues, such as inventory destocking, which has led to a decline of 10.9% for some health care companies. This drawdown is particularly concerning since it surpasses that seen by broader indices like the S&P 500.
Some businesses have consistently delivered growth due to their durable competitive advantages. However, based on the current market situation and conditions, some healthcare stocks stand out as cautionary tales when it comes to long-term prospects.
Here are three health care stocks that investors might consider passing over:
Myriad Genetics (MYGN)
Founded in 1991 as a pioneer in translating genetic discoveries into clinical applications, Myriad Genetics is known for developing genetic tests that guide treatment decisions and provide insights across oncology, women’s health, and mental health.
Despite its market presence over the years, Myriad’s sales have been flat over the last five, indicating it has struggled to expand during this period. Furthermore, negative impacts on earnings per share of 34.9% annually suggest a persistent performance degradation. The issue is compounded by an aggressive pursuit of growth that has led to value destruction.
Its valuation ratio, which stands at 140.9x forward price-to-earnings (P/E), suggests significant investor optimism despite these challenges. This ratio makes investors question the company’s pricing strategy given the flat revenue and negative earnings per share trend.
If MYGN is on your radar for portfolio additions, reviewing a comprehensive research report is advisable to gain insights into its financial performance.
IQVIA (IQV)
Market capitalization standing at a significant $26.57 billion, IQVIA has a presence in providing clinical services and analytics that aid drug development. Emerging from the 2016 merger of Quintiles and IMS Health, it helps pharmaceutical companies make informed decisions.
Despite its prominent position in healthcare service provision, IQV IA faces concerns over disappointing constant currency revenue growth for the past two years, signaling lower demand than anticipated. Estimated sales growth of only 3% for the next twelve months further reinforces apprehension about its future prospects. The issue is compounded by below-average returns on capital, pointing towards difficulties for management in identifying compelling investment opportunities.
Traded at 13x forward P/E, IQV IA’s pricing reflects market concerns about its long-term performance and growth potential. Understanding this situation thoroughly requires a closer look at our detailed research report, which can be accessed without any charge.
Repligen (RGEN)
Boasting a bioprocessing portfolio built through several strategic acquisitions since 2012, Repligen engages in the development of technologies improving biological drug manufacturing processes.
However, these efforts have come up short during this cycle. Market challenges affect products and services alike with sales exhibiting significant decreases by up to 11% over the last two years. Moreover, despite acquisitions aimed at facilitating growth, a lack of organic revenue growth in the recent past is concerning and suggests that future reliance on M&A for growth cannot compensate for this lag.
The drop in adjusted operating profits over the past couple of years as sales dipped points towards management’s struggle to adjust operational costs adequately to changing circumstances. As it stands now with its valuation at 84.8x forward P/E, market analysts would do well reviewing an in-depth analysis before any decision regarding portfolio adjustments and including RGEN within their equity holdings.
Stocks that Continue to Thrive
Market conditions have witnessed uncertainties as we delve into the realm of the unknown for policies impacting the market in the following year. While many analyze and speculate, our focus has shifted towards businesses capable of excelling regardless of current or future economic environments.
For those keen on navigating complex financial landscapes or seeking out their next significant investment, building on past successes could hold a clue to this potential success.
For those seeking investments with market-beating returns beyond 2024, consider the performance of our curated list of high-quality stocks, now reaching impressive 5-year gains. Here is why selecting diverse equities such as these in your diverse portfolio may prove beneficial.
Among past winners are some familiar stock names that have stood the test of time despite changing circumstances and economic conditions, while others offer a more understated yet equally valuable addition to any investment portfolio.
To make the leap into building lasting fortunes from informed stock selection decisions, discover the secrets behind these successful companies with free access now at StockStory.
